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Abstract
Anthrax lethal factor (LF) is a Zn
+2-dependent metalloprotease that cleaves several MAPK kinases and is responsible for the
lethality of anthrax lethal toxin (LT). We observed that a recombinant LF (LF-HMA) which differs from wild type LF (LF-A) by
the addition of two residues (His-Met) to the native Ala (A) terminus as a result of cloning manipulations has 3-fold lower
potency toward cultured cells and experimental animals. We hypothesized that the ‘‘N-end rule’’, which relates the half-life
of proteins in cells to the identity of their N-terminal residue, might be operative in the case of LF, so that the N-terminal
residue of LF would determine the cytosolic stability and thereby the potency of LF. Mutational studies that replaced the
native N-terminal residue of LF with known N-end rule stabilizing or destabilizing residues confirmed that the N-terminal
residue plays a significant role in determining the potency of LT for cultured cells and experimental animals. The fact that a
commercially-available LF preparation (LF-HMA) that is widely used in basic research studies and for evaluation of vaccines
and therapeutics is 3-fold less potent than native LF (LF-A) should be considered when comparing published studies and in
the design of future experiments.
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Introduction
Anthrax is a disease caused by spore-forming, Gram-positive
bacterium, Bacillus anthracis. The virulence of B. anthracis depends
on production of two major virulence factors-the gamma-linked
poly-D-glutamic acid capsule and anthrax toxin. The toxin is
composed of protective antigen (PA) and two catalytic moieties,
lethal factor (LF) and edema factor (EF) [1,2]. The binary
combination of PA and LF is known as lethal toxin (LT), while PA
and EF together constitute edema toxin (ET). PA is the central
receptor-binding component which delivers LF and EF into the
cytosol of mammalian cells. EF is a calmodulin-dependent
adenylate cyclase [3] while LF is a Zn
+2-dependent metallopro-
tease that cleaves several MAPK kinases [4,5].
InjectionofLTinducesdeathofexperimentalanimals,whichcan
occur in 1–2 days in mice or as little as 38 minutes in rats. LT has
been found to have many physiological and pathological effects
[6,7], including but not limited to impairing endothelial barrier
function [8] and glucocorticoid receptor activity [9], and inducing
necrosis or apoptosis in macrophages [10,11]. LT induces a shock-
like vascular collapse similar to that observed in anthrax-infected
animals and humans. Because LT plays a key role in virulence
during anthrax infections, substantial effort has been directed to the
development of vaccines and therapeutics that target this toxin.
These efforts depend on the availability of reliable, economical
sources of purified toxin components having consistent and well
characterized properties. Various expression hosts have been used
for the purification of PA and LF, including Escherichia coli, Bacillus
subtilis, and B. anthracis [12–14]. This laboratory originally produced
native PA, LF, and EF from the avirulent B. anthracis Sterne strain
[15,16] and later developed systems for efficient expression and
purification of PA and LF as recombinant molecules from avirulent
strains of B. anthracis [17,18]. In the course of these studies we noted
differences in LF potency between sources and individual
preparations which suggested that variability at the N-terminus of
the protein might have an impact on potency. This was consistent
with prior studies showing that the stability of LF fusion proteins in
the cytosol of cells depended on identity of the N-terminal residue
[19] pointing to the involvement of the N-end rule in determining
susceptibility to ubiquitinylation and subsequent degradation by the
proteasome [20].
The N-end rule of protein degradation relates the in vivo stability
of a protein to the identity of its N-terminal residue. Ubiquitin (Ub)
ligases target protein substrates that bear specific (destabilizing) N-
terminal residues [20,21]. The corresponding degradation signal
called the N-degron consists of a protein substrate’s destabilizing
N-terminal residue and an internal Lys residue, the latter being the
site of attachment for a poly-Ub chain. A ubiquitylated substrate is
then targeted to and degraded by the proteasomes [22]. It is of
interest to note that unlike many bacterial toxins that have a strong
bias of Arg over Lys [23], LF has a substantial number of Lys in
the N-terminal region that are potential ubiquitination sites. A
truncated LF protein, LF1–254 (also designated LFn), containing the
PA binding domain of LF, was shown to follow the N-end rule in
cells [19], since addition of destabilizing residues at its N-terminus
(e.g., Arg) increased the protein’s degradation rate in reticulocyte
lysate and cells. LF produced by B. anthracis contains the sequence
AGGH, which becomes the N-terminus of the mature protein
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peptidase. In our studies we initially noted that the presence of two
additional N-terminal residues in recombinant LF decreased its
potency approximately 3-fold. This prompted a systematic study of
the role of the N-terminus, which is reported here.
Methods
Cell culture and cytotoxicity assays
RAW264.7 cells were used for cytotoxicity studies. Cells were
grown in Dulbecco’s modified Eagle medium containing 2 mM
Glutamax, 25 mM HEPES and 50 mg/ml gentamicin supple-
mented with 10% fetal calf serum (all from Invitrogen, Carlsbad,
CA) at 37uCi n5 %C O 2. For cytotoxicity assays, cells were plated
in 96-well plates 24 h prior to use. Cells were treated with varying
concentrations of LF in the presence of a fixed concentration of PA
(250 ng/ml) for 3–4 h. Cell viability was assessed by the addition
of MTT [3-(4,5-dimethylthiazo-2-yl-02,5-diphenyltetrazolium
bromide] (Sigma, St. Louis, MO) at a final concentration of
0.5 mg/ml, incubation for another 45 min at 37uC, and release of
the blue pigment produced by viable cells using 0.5% (w/v)
sodium dodecyl sulfate (SDS), 25 mM HCl in 90% (v/v)
isopropanol. A microplate reader was used to measure the A570
to quantify cell survival.
Plasmids and mutagenesis
Plasmid pSJ115 [18] was used to express wild type and mutated
LF proteins. The Quick Change-II site directed mutagenesis kit
(Stratagene, La Jolla, CA) was used for manipulations in pSJ115
according to the manufacturer’s instructions. Mutations were
confirmed by DNA sequencing, and for each construct the entire
gene was also sequenced to confirm that there were no other
mutations present.
Production and purification of proteins
Proteins PA, FP59, and all LF variants were produced and
purified from B. anthracis strain BH450 as described earlier [18,24]
. Samples of LF used for comparison were purchased from List
Biological Laboratories (Campbell, CA).
Processing of LF proteins by factor Xa
Factor Xa (Novagen, Madison, WI) was used to cleave off the
Myc tag from purified, mutated LF proteins. In a typical small
scale digestion, 25 mg of protein was incubated at room
temperature with 0.3 units of factor Xa in 1 X reaction buffer
containing 50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 5 mM
CaCl2. After 14 h incubation at 4uC, 2 mM EDTA and 1 mM
DTT was added. Large scale preparations used the same
conditions. N-terminal sequencing was performed to determine
the N-terminus of LF proteins.
LF cellular affinity determinations
The affinity of LF proteins to cell-bound PA was measured by
Schild plot analyses [24,25]. These studies used CHO WTP4 cells,
which are not killed by LF, and the cytotoxic fusion protein FP59
[26,27], in which the N-terminus of LF is fused to the ADP-
ribosylating domain of Pseudomonas exotoxin A. CHO cells were
maintained in alpha minimal essential medium supplemented with
5% fetal bovine serum, 2 mM glutamine, 50 mg of gentamicin/ml,
and 25 mM HEPES. In Schild plot analyses, cells were incubated
with various concentrations of FP59 plus PA (constant at 12 nM)
in the presence of different fixed concentrations of the LF protein
being analyzed, which acted as a non-toxic competitor of FP59.
After 3 h, the toxins were replaced by media containing 10 mM
NH4Cl to inhibit further toxin delivery to the cytosol [24,28,29].
Cells were then incubated for 48 h at 37uC followed by MTT
addition for cell viability determination. Data were analyzed by
Graphpad Prism software to calculate binding constants.
Animal experiments
Female Fischer 344 rats (Taconic Farms Germantown, NY, 170–
190 g) were injected via the tail vein (200 ml/rat) with a mixture of
PA+LF (LT), prepared in sterile PBS. Concentrations and doses of
LT refer to the amounts of each component (i.e. 10 mgL Ti s1 0mg
PA+10 mg LF and 100 mg LT is 100 mgP A +100 mg LF). The same
PA preparation was used in combination with different LF proteins.
Rats were observed continuously for signs of malaise and mortality.
Balb/cJ mice (Jackson Labs, Bar Harbor, ME) were injected IP
(1 ml/mouse) with different doses of LT and monitored for up to 7
days for malaise and mortality. All animal experiments were
performed under protocols approved by the NIAID Animal Care
and Use Committee.
Results
Toxicities of LF proteins produced from avirulent B.
anthracis strains
LF has been expressed and purified in many laboratories from a
variety of expression hosts, including E. coli, B. subtilis and B.
anthracis. This laboratory produces LF from non-toxigenic strains
of B. anthracis. Originally, we prepared LF as well as PA and EF
from the Sterne strain of B. anthracis [15,16] grown in a manner
similar to that used to produce the currently licensed anthrax
vaccine [30]. A sample of LF produced in this way, kept frozen at
280uC since 1984, and here designated LF-A/St, was available
for use in the current study (Fig. 1). Subsequently, to facilitate
production of mutated proteins and to eliminate concerns about
contamination of one toxin component with the others, the LF
gene was cloned into a recombinant shuttle vector, pSJ115, which
was transformed into various B. anthracis strains cured of the pXO1
and pXO2 virulence plasmids [18]. LF expressed from pSJ115 is
here termed LF-HMA to denote the presence of the two residues
His-Met (HM) added at its N-terminus due to the cloning
manipulations. This expression system is licensed to List Biological
Laboratories (Campbell, CA), and the LF sold by them is therefore
also LF-HMA. All the LF proteins produced in our lab from B.
anthracis are secreted proteins containing signal peptides that are
cleaved by the endogenous signal peptidases during secretion.
Over the course of several years, we noted that multiple batches
of LF-HMA were less toxic than LF-A/St (data not shown). Based
on the hypothesis that the reduced toxicity of LF-HMA was due to
the two additional residues (HM), we mutated pSJ115 to remove
the two codons specifying HM, producing LF-A, with the native
N-terminal sequence matching LF-A/St (Fig. 1). Because secreted
proteins can undergo degradation by co-secreted bacillus proteases
in the bacterial culture supernatant or during protein purification,
we also constructed LF proteins with cleavable N-terminal
sequences or tags. Thus, the LF-A/X protein (Fig. 1) was obtained
from a secreted precursor protein processed by the bacterial signal
peptidases to yield a LF protein having a 6-residue N-terminal
extension. The purified protein was then cleaved with the factor
Xa protease to yield an N-terminal Ala (Fig. 1). A similar construct
was made in which the factor Xa cleavage site is preceded by a
Myc tag, which can be used for affinity purification and for
detection (LF-A/MyX, Fig. 1). The ability to precisely control the
N-terminus of each protein by factor Xa cleavage also eliminated
any heterogeneity that might occur if the selection of cleavage site
by the signal peptidase was inexact. We found that the insertion of
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peptide had no measurable impact on protein yields (data not
shown). Precursor proteins purified from supernatants of B.
anthracis BH450 were cleaved with factor Xa to remove the N-
terminal extensions and to obtain mature mutated LF proteins
with different N-terminal amino acids (Fig. 1). Western blot studies
with anti-Myc antibodies were used to verify the initial presence of
the Myc tags and their subsequent removal by cleavage with factor
Xa (data not shown).
LF-A and LF-A/X showed enhanced toxicity as compared to
LF-HMA in macrophage cytotoxicity assays (Fig. 2A, Table 1).
The EC50 values (concentration required to kill 50% of the cells) of
LF-A and LF-A/X were approximately 3-fold lower than those of
LF-HMA (Fig. 2A, Table 1), and were comparable to the values
found in other experiments for LF-A/St (data not shown). Because
LF-A/St, LF-A and LF-A/X have the exact same N-terminal
sequence while LF-HMA has two additional residues at the N-
terminus (Fig. 1) but the latter has lower potency, we performed
more extensive analyses of the role of the N-terminal residue,
described below.
The N-end rule is predictive of LF potency
The ‘‘N-end rule’’ states that for certain proteins, the identity of
the N-terminal amino acid residue determines the rate of cytosolic
ubiquitinylation and thereby the rate of degradation by the
proteasomes. The fact that the His at the N-terminus of the LF-
HMA is classified as a destabilizing residue compared to Ala, at
least in Saccharomyces cerevisiae [31] and in Vero-Dr22 cells [32] ,
suggested that the N-end rule might apply to LF stability in cells.
To examine this possibility, the N-terminus of LF was substituted
with the amino acid residues Gly, Arg, Met, Phe, and His (Fig. 1).
These proteins and LF with the native N-terminal Ala were
produced with the Myc tag and factor Xa site, and designated as
LF-Z/MyX (Fig. 1, with Z representing the substitution and X
denoting presense of a factor Xa cleavage site). According to the
N-end rule, Gly and Met are classified as stabilizing residues while
Arg and Phe are considered destabilizing ones [22,31,33].
Cytotoxicity assays in the mouse macrophage RAW264.7 cell
line were performed to compare the activities of the mutated LF
proteins. LF with the most stabilizing residue, Met (LF-M/MyX)
was as toxic as wild type sequence LF-A/MyX but more toxic than
LF with destabilizing residues Phe (LF-F/MyX) and Arg (LF-R/
MyX) (Fig. 2B). LF proteins with His (LF-H/MyX) or Gly (LF-G/
MyX) at their N-terminus were less toxic than LF-M/Myx and
LF-A/MyX but more toxic than LF-F/MyX and LF-R/MyX
(Table 1). The destabilizing residue Phe clearly had a large impact
on toxin activity, as the EC50 was increased ,6-fold compared to
LF with the most stabilizing residue, Met (Table 1). These data
clearly support the hypothesis that the N-end rule applies to LF
potency in cells, likely by controlling cytosolic stability of the toxin.
In vivo role of N-terminal residue of LF
The rapid lethality that occurs in Fischer rats following
intravenous injection of LT provides an assay that is widely used
Figure 1. Schematic representation of various LF proteins. All proteins (except LF-A/St which is wild type LF produced from Sterne strain)
were generated as secreted proteins from B. anthracis BH450. All proteins contained a signal peptide that is cleaved by signal peptidases during
secretion. Constructs with a factor Xa recognition sequence alone or preceded by the Myc epitope tag are labeled ‘‘/X’’ or ‘‘/MyX’’, respectively. These
proteins were produced as precursor proteins followed by cleavage with factor Xa protease to generate the indicated N-termini. Residue (Z) circled in
red indicates the residue mutated for each protein, i.e., Z=A, H, M, R, F, G in different mutated LF constructs.
doi:10.1371/journal.pone.0003130.g001
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done accurately, the response is highly predictable, with little
deviation in time to death (TTD) for a given dose. Historically, this
laboratory’s TTD following injection of 10 mg LT using various
preparations of LF-HMA fell in a range of 73–110 min. We found
that the same dose of LT using LF-A resulted in an average TTD
of 63 min (Table 2). Furthermore, LF constructs with the N-end
rule stabilizing residues Met or Gly, and the intermediate
stabilizing residues, His and Ala, resulted in a similarly low
TTD (Table 2). LF constructs having the N-end rule destabilizing
residues Arg and Phe, however, showed higher average TTD of
78 min and 122, respectively (Table 2). The injection of a high
dose of 100 mg LT/rat did not reduce the TTD for LF-HMA
preparations below 50 min (Table 2). A 100 mg dose of LF-A,
however, resulted in a TTD of 38–39 min in every rat. LF-A/X,
produced by cleavage with factor Xa, also resulted in a similar
rapid 37 min TTD in every rat. It was gratifying that these results
exactly match, to the minute, the theoretical minimum TTD
derived by extrapolation in studies done in 1984 [34] with a LF
preparation equivalent (and possibly identical) to the LF-A/St
used in these studies.
This laboratory has also used the mouse lethality test
extensively. We found that LF-A/St, the material prepared in
1984, was significantly more potent than LF-HMA (Fig. 3A). We
extended these studies and tested LF-A, LF-A/X, LF-R/MyX,
LF-F/MyX, LF-G/MyX, LF-M-MyX and LF-H/Myx in Balb/cJ
mice at two doses, 100 and 40 mg injected IP (Fig. 3B and 3C). At
the 100 mg dose, LF-HMA was less potent than all tested LF
preparations except LF-G/MyX and LF-R/MyX. These two
proteins resulted in extended malaise in mice, with no toxin-
induced animal deaths (LF-F/MyX was not tested in this study).
All other LF preparations had significantly lower TTD than LF-
HMA. At the 40 mg dose the LF-M/Myx was clearly the most
potent construct, being the only preparation resulting in 100%
lethality at this low dose. Thus the results from the in vivo mouse
studies, despite having higher variability than the rat studies, did
support the hypothesis of involvement of N-end based stability of
proteins in animal toxicity.
Affinity of LF proteins for cell-bound PA
To determine whether the difference in the activity of LF-HMA
and LF-A is caused by differences in binding affinity, we measured
the apparent affinities (Kd) of LF-HMA and LF-A for protective
antigen (PA). For these studies, CHO WTP4 cells which are
anthrax LT-resistant but sensitive to FP59 (a chimeric toxin of LFn
and catalytic sub-unit of Pseudomonas exotoxin A) were used. FP59
is highly toxic to CHO WTP4 cells due to its catalytic activity i.e.
ADP-ribosylation of elongation factor-2 and blocking of protein
synthesis [27]. Binding affinity for different LF-HMA and LF-A
proteins was compared by measuring the sensitivity of CHO
WTP4 cells to PA plus FP59 when LF-HMA or LF-A were used as
competing inhibitors of toxicity. Addition of fixed concentrations
of LF-HMA or LF-A shifted the PA plus FP59 cytotoxicity dose-
response curves (Fig. 4). The EC50 values of FP59 plus PA
cytotoxicity dose responses in the presence of various fixed
concentrations of LF-HMA or LF-A were determined and a non-
linear regression fit analysis was performed using the equation
Y=2log(X+10log Kd)2P, where Y=2log(EC50) (nM), X=[LF-
HMA] or [LF-A] (nM), and P is a constant, (see http://www.
graphpad.com/curvefit/schild.htm for details). The results show
that the apparent affinities of LF-HMA and LF-A to PA are very
similar, 0.19 nM and 0.17 nM, respectively (Fig. 4). Thus, these
data show that the difference in the activity of LF-HMA and LF-A
is not due to the altered binding to PA.
Discussion
The production of LF (and PA) from B. anthracis has a number of
advantages that, together with the improvements reported here,
recommend its continue use as a host for production of LF and
PA, which have value as biological research reagents and as
components of anthrax vaccines. Secretion to the culture
supernatant from the native host organism assures that processing
(e.g., by the signal peptidase) and folding will be optimal. Because
Figure 2. Cytotoxicity of LF proteins to RAW264.7 cells.
RAW264.7 cells were incubated with various concentrations of LF-
HMA, LF-A, and LF-A/X proteins (A) or LF proteins with mutated N-
termini (B) and a fixed concentration of PA (250 ng/ml). Cell viability
was assessed at 3 h. Percent viability was calculated relative to cells
treated with medium (no toxin).
doi:10.1371/journal.pone.0003130.g002
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truncation and inactivation of the global transcriptional regulator
PlcR [35,36], the secreted toxin proteins typically constitute more
than half of the supernatant proteins. In this laboratory, a 3-L
shake flask culture typically yields 200 mg of purified LF. A final
advantage when the LF is to be used in studies of signal
transduction pathways is the absence of gram-negative endotoxin.
Data collected over several years in our laboratory indicated
that purified LF-HMA, either made in our laboratory or
purchased from List Laboratories, was less toxic in macrophage
toxicity assays when compared to LF purified from the B. anthracis
Sterne strain. LF-HMA differed from LF-A/St only in two N-
terminal residues (His and Met). We hypothesized that the
decreased potency of LF-HMA could be due to the lower stability
of protein once it is internalized to the cell cytosol, as might occur
if the N-end rule were operative for LF. Previous studies had
provided evidence that the N-end rule applied to proteins
containing the N-terminal LF domain [19], and since recognition
of proteins by the ubiquitinating enzymes typically depends on a
small region near the N-terminus of proteins, it was expected that
the N-end rule would also apply to native, full-size LF. We tested
this hypothesis by constructing recombinant LF proteins having
the same sequence as LF-A/St, either as a result of signal peptide
cleavage, or by cleavage of precursor proteins at a factor Xa
protease site (with or without a Myc tag upstream). All three such
proteins, LF-A, LF-A/X and LF-A/MyX, had three-fold lower
EC50 values (i.e., higher potencies) than LF-HMA in macrophage
toxicity assays, similar to what was historically observed for LF-A/
St. In the Fischer rat assay of LT potency, the lowest TTD
observed for LF-HMA was 50 min. In contrast, LF-A and LF-A/
X were lethal to rats within 37–39 min, respectively, in exact
correspondence to a theoretical minimum TTD previously
obtained by extrapolation in 1984 [34].
We further tested the role of N-end rule in controlling the LF
stability in cells by producing mutant LF proteins with different N-
termini. The N-end rule predicts that proteins bearing charged
Table 1. Toxicity of LF proteins to RAW 264.7 cells.
LF Proteins EC50 (ng/ml) * Source of data Estimated half life (h)#
Reticulocyte lysates Vero-Dr22 cells Yeast
LF-HMA 3.7 Fig. 2A 3.5 1.08 0.16
LF-A 1.2 Fig. 2A 4.4 2.9 .20
LF-A/X 1.1 Fig. 2A 4.4 2.9 .20
LF-A/MyX 1.4 Fig. 2B 4.4 2.9 .20
LF-R/MyX 6.1 Fig. 2B 1 0.83 0.03
LF-G/MyX 4.0 Fig. 2B 30 9.8 .20
LF-F/MyX 9.5 Fig. 2B 1.1 0.51 0.05
LF-H/MyX 3.9 Fig. 2B 3.5 1.08 0.16
LF-M/MyX 1.5 Fig. 2B 30 19.3 .20
*EC50 is the (effective) concentration of toxin required to kill 50% of cells. RAW264.7 cells were incubated with LF proteins and 250 ng/ml PA and viability determined as
described in Methods.
#Estimated half life is that measured for a Beta-galactosidase test protein having the same N-terminus when incubated in rabbit reticulocyte lysate or when produced in
vivo in Saccharomyces cerevisiae [31]. Half life in Vero-Dr22 cells mentioned here is for diphtheria toxin as reported earlier [32].
doi:10.1371/journal.pone.0003130.t001
Table 2. Toxicity of LF proteins in rats.
LF Proteins Dose (mg/rat) Survival* TTD (min) Average TTD (min)
LF-HMA 10 0/25 97, 97, 102, 130, 91, 92, 93, 93, 93, 93, 94, 94, 95, 73, 75, 95, 95,
96, 96, 97, 102, 102, 106, 107, 109
97
LF-A 10 0/25 62, 70, 53, 55, 56, 57, 57, 61, 61, 62, 65, 65, 66, 71, 76, 60, 60, 60,
55, 58, 59, 71, 73, 75, 76
63
LF-R/MyX 10 0/3 80, 77, 76 78
LF-F/MyX 10 0/3 98, 145, 124 122
LF-G/MyX 10 0/3 66, 65, 66 66
LF-M/MyX 10 0/3 60, 65, 65 63
LF-H/MyX 10 0/3 62, 65, 65 64
LF-A/MyX 10 0/3 62, 63, 61 62
LF-HMA 100 0/3 51, 51, 50, 54, 53 52
LF-A 100 0/3 39, 39, 39, 38, 38, 38, 38, 39 39
LF-A/X 100 0/6 37, 37, 37 37
*Fisher 344 Rats were injected with 10 mg PA or 100 mg PA plus equivalent amount of each LF preparation (IV) and monitored for minutes to death.
doi:10.1371/journal.pone.0003130.t002
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Phe or Trp) N-termini are targeted more rapidly to the
proteasomes. These residues are termed ‘‘destabilizing’’ residues.
On the other hand, certain N-terminal residues such as Met or Gly
are highly stabilizing [31]. The N-end rule has been observed for
many proteins which have shown similar but not identical patterns
in terms of the effect of a specific amino acid on the protein
stability [32,33,37,38]. In our studies, LF with the stabilizing
residue Met was the most toxic in both cell culture and two animal
models. As predicted by the N-end rule, the LF protein with the
stabilizing Gly N-terminus was comparable to a LF construct with
native wild type amino terminus (Ala) in cell toxicity studies and
the rat lethality model. Addition of the potent destabilizing
residue, Phe, to LF resulted in significantly decreased LF potency
for both macrophages and rats, while an intermediate destabilizing
residue, Arg, showed predictable intermediate effects both in vitro
and in vivo. The amino acid His has been shown to have variable
destabilizing effects for different proteins depending on the cell
type [31,32]. In the case of LF, both His and the native N-terminal
residue, Ala, did not have a destabilizing effect and behaved
similarly to the LF construct with the stabilizing Gly residue,
however, they behaved differently in cell toxicity experiments. The
results of these mutational studies, especially those observed for the
highly stabilizing residue Met (in LF-M/MyX) and the highly
destabilizing residue Phe (in LF-F/MyX) clearly indicate that the
N-terminus has a significant impact on the activity of lethal factor
both in cell toxicity studies, as well as in animals.
Although our data implicates the N-end rule as determining and
explaining the relative potencies of the LF proteins discussed here,
we cannot exclude that other factors may contribute to the effects
we observed. The N-terminal domain of LF initiates the entrance
of LF into the channel formed by the PA heptamer, but residues
near the N-terminus are not involved in binding to PA [39,40],
nor is there evidence that they are needed for translocation. Thus,
N-terminal truncation of LF by more than 13 residues was needed
to strongly decrease the ability of LF to enter the PA heptamer
channel [41], suggesting that the identity of individual residues
near the N-terminus is not critical in translocation. This makes it
less likely that the substantial effects we see from substitution of
single N-terminal residues on activity are due to alternation of the
translocation process.
The clear role of LF stability in the Fischer rat model of LT
sensitivity is especially striking. The variability in TTD and
potency of the different LF proteins tested in this study can easily
explain the high degree of variability seen in the dosages required
by different laboratories for LT lethality in various animal models.
LF preparations purified from bacterial hosts can yield a
Figure 3. Toxicity of LF proteins to mice. (A) LF-HMA and LF-A/St
(100 mg) were injected in Balb/cJ mice in combination with 100 mgP A
via the IP route and survival was monitored for 120 h. Each group
contained n=5 mice. (B) LF proteins (100 mg) were injected in Balb/cJ
mice in combination with 100 mg PA via the IP route and survival was
monitored for 120 h. Mouse numbers used in this experiment were as
follows: LF-HMA (n=9), LF-A (n=9), LF-A/X (n=5), LF-G/MyX (n=3) and
all other groups n=4. (*) The animals in LF-G/MyX and LF-R/MyX groups
exhibited substantial malaise starting at 24 h and throughout the
experiment and were euthanized at 128 h to prevent suffering in
accordance with approved animal protocols. (C) LF preparations
(40 mg) were injected in Balb/cJ mice in combination with 40 mgP A
via the IP route and survival was monitored for 120 h. Mouse numbers
used in this experiment were as follows: LF-HMA (n=14), LF-A (n=9),
LF-A/X (n=5) and all other groups n=4. (**) The surviving animals in
these groups did not display any signs of malaise over the last 48 h of
the experiment.
doi:10.1371/journal.pone.0003130.g003
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(data not shown). The mixture of different N-termini in a
particular LF preparation can greatly affect the potency. In fact,
in our laboratory, where LF production is a routine and frequently
performed procedure, we have on rare occasions obtained
preparations of LF that produce much higher TTD in the
uniquely sensitive Fischer rat model when compared to previously
validated standard LF preparations. Similarly, different potencies
have also been noted with commercially available LF preparations
(data not shown). We believe that variable levels of different N-
termini in each preparation, generated through the purification
process or by bacterial proteases may explain potency differences
in these and other laboratories’ preparations. We suggest that new
approaches to LF preparation, such as generation of uniform N-
end termini as demonstrated in this work, offers a route to limiting
this variability.
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Figure 4. Evaluation of the apparent binding affinities of LF-HMA and LF-A for PA using Schild Plot analyses. CHO WTP4 cells were
incubated with various concentrations of FP59 plus a set concentration of PA (12 nM) and different concentrations of LF-HMA (A) or LF-A (B) for 3 h.
After toxin removal, cells were incubated with the toxin-free medium containing 10 mM NH4Cl for 48 h before assessment of cell viability. Schild Plot
analyses were performed as described in ‘‘Methods’’ to assess Kds of each LF protein for PA. Inserts shown in panels A and B are non-linear regression
curves obtained from these analyses using GraphPad Prism.
doi:10.1371/journal.pone.0003130.g004
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